Development of a Eudragit-Chitosan Nanosystem for the pH-Dependent Transport of Duloxetine to the Brain: Synthesis, Characterization and In Silico Modeling Analysis

The purpose of this study was to synthesize duloxetine (DLX)- loaded Eudragit-Chitosan (Eud-CHT) nanoparticles enclosed in an oral gelatin capsule and evaluate the potential transport DLX blood-brain barrier (BBB)for improved neuro-availability. utilization Eudragit® with chitosan offers a pH-dependent controlled drug release. physicochemical properties formulated DLX-loaded Eud-CHT nanosystem were confirmed using various characterization techniques. SEM nanoparticle morphology pore size distribution. particle 100 ± 73,41 nm, polydispersity index (PDI) 0,283 zeta 16±2,79 mV. Drug entrapment efficacy (DEE) 72% attained, molecular modelling predicted efficient controllable delivery system. release from evaluated at pH1.2, pH 6.8 7.4. At 6.8, 40 % released, only 20 1.2 35% This demonstrated DLX's nanosystem's shielding effect gastric pH. In addition, HEK 293 neural cells non-toxicity DLX-Eud-CHT nanosystem. silico revealed composite outer cationic surface attributable EUD moieties on for preferential cell recognition uptake anionic interface. combined trials results synthesis showed that these could be utilized as potentially invaluable formulation